Current Management of Polycystic Ovary Syndrome. (Record no. 88226)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11291nam a22005533i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC3399991 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729125442.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2010 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781107711020 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781906985417 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC3399991 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL3399991 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr10491819 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)816863530 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RG480.S7.C87 2010 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 618.1100941 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Balen, Adam. |
| 245 10 - TITLE STATEMENT | |
| Title | Current Management of Polycystic Ovary Syndrome. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | London : |
| Name of producer, publisher, distributor, manufacturer | Cambridge University Press, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2010. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2010. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (240 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 490 1# - SERIES STATEMENT | |
| Series statement | Royal College of Obstetricians and Gynaecologists Study Group Series |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Title page -- Contents -- Participants -- Additional contributors -- Declarations of personal interest -- Preface -- 1 Overview and definitions of polycystic ovary syndrome and the polycystic ovary -- Introduction -- What is polycystic ovary syndrome? -- Defining the polycystic ovary: historical and histopathological considerations -- Ultrasound descriptions of the polycystic ovary -- Multicystic and polycystic ovaries -- Transvaginal ultrasound -- Stromal echogenicity -- Three-dimensional ultrasound, Doppler and MRI -- Exclusion of related disorders -- Conclusion -- Key points -- References -- 2 Genetics and pathogenesis of polycystic ovary syndrome -- Introduction -- Developmental origin of PCOS -- Genes and PCOS -- Role of the intrauterine environment -- Role of the external environment: diet, obesity and PCOS -- Summary -- References -- 3 Ethnic variations in the expression of polycystic ovary syndrome -- Introduction -- Defining race and ethnicity -- Evidence for ethnic variations in the expression of PCOS -- Historical background -- Ethnic variations of obesity, insulin resistance and the metabolic syndrome in PCOS -- The Asian perspective -- Non-Asians -- Ethnic variation of hyperandrogenism in PCOS -- East Asians -- Other ethnic groups -- Ethnic interrelationships of metabolic problems and hyperandrogenism manifestations of PCOS -- Epidemiological variations of insulin resistance and the prevalence of PCOS - are they in parallel? -- Ethnic differences in diagnostic thresholds for polycystic ovaries -- Ethnic differences in quality of life -- Summary and conclusion -- Acknowledgements -- References -- 4 Quality of life for women with polycystic ovary syndrome -- Introduction -- What is health-related quality of life? -- Measuring HRQoL -- Types of instrument available to measure quality of life in women with PCOS. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Generic questionnaires -- Overall impact of PCOS on HRQoL -- Comparisons with controls (other gynaecological populations) -- PCOS and mental health -- Impact of PCOS-associated obesity on HRQoL -- Problems with proxy assessments of HRQoL -- Impact of PCOS-associated infertility and sexual functioning on HRQoL -- Treatments for PCOS that have measured associated changes to HRQoL -- Conclusion -- Summary of key points -- References -- 5 Insulin resistance, the metabolic syndrome and polycystic ovary syndrome -- Introduction -- Definitions and diagnosis -- Mechanism of insulin resistance in PCOS -- Interactions between the metabolic syndrome and ovarian function -- Insulin as a co-gonadotrophin -- Inflammation and the ovary -- PCOS as a marker for type 2 diabetes -- PCOS as a marker for cardiovascular disease -- PCOS and non-alcoholic steatohepatitis -- PCOS and implications for family members -- Treatment of PCOS and the metabolic syndrome -- Conclusion -- References -- 6 Management of polycystic ovary syndrome through puberty and adolescence -- Introduction -- Diagnosis -- The menstrual cycle during adolescence -- Ovarian appearance on ultrasound -- Hormonal changes during puberty -- Clinical presentation -- Developmental origins of PCOS -- Differential diagnosis -- Treatment -- Oral contraceptive pills -- Metformin -- Thiazolidinediones -- Antiandrogens -- Recommendations -- Clinical evaluation -- Investigations -- Treatment -- Monitoring -- Conclusion -- References -- 7 Long-term health risks of polycystic ovary syndrome -- Increased cardiovascular risk -- Surrogates for cardiovascular disease -- Traditional measures and the metabolic syndrome -- New markers -- Waist circumference and HDL cholesterol -- PCOS as a risk factor on its own -- Recommendations -- Risk for type 2 diabetes and impaired glucose tolerance -- Complications of obesity. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Gynaecological malignancies -- Endometrial hyperplasia and cancer -- Breast cancer -- Ovarian cancer -- Conclusion -- References -- 8 Approaches to lifestyle management in polycystic ovary syndrome -- Introduction -- Prevalence of obesity and PCOS -- Evidence that early weight gain favours the development of PCOS -- Pathophysiological aspects of adipose tissue in PCOS -- Obesity worsens the PCOS phenotype and associated metabolic alterations -- Treatment of obesity improves PCOS -- Lifestyle management -- Lifestyle modification and infertility -- Conclusion -- References -- 9 Management of obesity in polycystic ovary syndrome, including anti-obesity drugs and bariatric surgery -- Introduction -- Lifestyle modification -- Anti-obesity medication -- Orlistat -- Sibutramine -- Bariatric surgery -- Background -- Bariatric surgery and PCOS -- Pregnancy after bariatric surgery -- Conclusion -- References -- 10 Definition of hyperandrogenism -- Clinical hyperandrogenism -- Biochemical hyperandrogenism -- Assessment of anovulation -- Proposal for new criteria -- Clinical hyperandrogenism -- Laboratory hyperandrogenism -- Laboratory diagnosis of anovulation -- Summary -- References -- 11 Treatment of hyperandrogenism in polycystic ovary syndrome -- Introduction -- Acne -- General advice -- Managing according to clinical sub-type -- Treatment of non-inflammatory lesions -- Treatment of mild to moderate inflammatory lesions -- Topical therapies for post-inflammatory hyperpigmentation -- Alternative therapies and procedures -- Nodular lesions -- Non-inflammatory lesions -- Skincare and use of cosmetics -- Systemic therapies -- Inhibitors of adrenal androgen production -- Inhibitors of ovarian androgen production -- Oral contraceptives -- Gonadotrophin-releasing hormone agonists -- Androgen receptor blockers -- Spironolactone -- Flutamide -- Finasteride. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Insulin-sensitising drugs -- Conclusion on acne management in PCOS -- Hirsutism -- Topical therapy -- Eflornithine hydrochloride -- Systemic therapy -- COC pills -- Cyproterone acetate -- Spironolactone -- Gonadotrophin-releasing hormone agonists -- Finasteride -- Flutamide -- Insulin-sensitising drugs -- Female-pattern hair loss -- Minoxidil -- Antiandrogens -- Reductase inhibitors -- Conclusion -- References -- 12 Choices in the treatment of anovulatory polycystic ovary syndrome -- Introduction -- Weight loss -- Clomifene citrate -- Mode of action -- Dose -- Results -- Clomifene citrate treatment failure -- Monitoring -- Adjuvant treatment -- Aromatase inhibitors -- Mode of action -- Indications -- Dose -- Evidence -- Safety -- Metformin -- Mode of action -- Dose -- Evidence -- Safety -- Low-dose gonadotrophin therapy -- Principle -- Regimen -- Evidence -- Variations -- References -- 13 Predictors of ovarian response to ovarian stimulation: progress towards individualised treatment in ovulation induction -- Introduction -- Predictors of ovarian response in ovulation induction -- Predicting response to anti-estrogen therapy -- Predicting response to gonadotrophins -- Might genetic predictors be useful? -- Conclusion -- References -- 14 Surgical management of anovulatory infertility in polycystic ovary syndrome -- Introduction -- History -- Methods and dose -- Risks of adhesion formation and ovarian failure -- Endocrine changes after laparoscopic ovarian surgery -- Pregnancy rates -- Transvaginal approach -- Summary -- Key points -- Clinical practice points -- Future avenues for research -- References -- 15 The role of insulin-sensitising drugs in the treatment of polycystic ovary syndrome -- Introduction -- Metformin -- Premature pubarche -- Infertility -- Miscarriage and pregnancy complications -- Hirsutism -- Diabetes prevention. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Endometrial cancer prevention -- Conclusion -- Acknowledgements -- References -- 16 The role of in vitro maturation of oocytes for anovulatory polycystic ovary syndrome -- In vitro maturation of immature oocytes -- Variations -- Patient selection -- hCG priming -- Gonadotrophin ovarian stimulation -- ICSI -- Endometrial priming -- Metformin co-treatment -- Timing of immature oocyte retrieval in relation to follicular diameter -- Results -- Safety -- Summary -- References -- 17 Acupuncture and/or herbal therapy as an alternative or complement for relief of polycystic ovary syndrome-related symptoms -- Introduction -- Treatment of PCOS -- The physiological basis for acupuncture -- How may acupuncture act in women with PCOS? -- Evidence for the use of acupuncture in PCOS -- Effects on ovulation -- Effects on metabolic abnormalities -- Effects on mental health -- Effects on the sympathetic nervous system -- Continuing or completed RCTs on the effects of acupuncture in PCOS-related symptoms -- Herbal therapy for the relief of PCOS-related symptoms -- Herbs for ovulation induction -- Vitex agnus-castus -- White peony -- Sairei-to -- Mentha spicata Labiatae -- Herbs for metabolic abnormalities -- Berberine -- Cinnamon -- Labisia pumila -- Future perspectives -- Conclusion -- References -- 18 Consensus views arising from the 59th Study Group: Current Management of Polycystic Ovary Syndrome -- Diagnosis/pathophysiology -- Management -- Lifestyle and metabolic aspects -- Treatments -- Research -- Index. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | This book presents the findings of the RCOG Study Group on polycystic ovary syndrome - the most common endocrine disturbance of women in the UK. PCOS has a significant effect on quality of life and psychological morbidity and, as many specialists are involved in its management, a multidisciplinary approach is required. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Polycystic ovary syndrome. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Ovaries -- Cysts. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Franks, Stephen. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Homburg, Roy. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kehoe, Sean. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Balen, Adam |
| Title | Current Management of Polycystic Ovary Syndrome |
| Place, publisher, and date of publication | London : Cambridge University Press,c2010 |
| International Standard Book Number | 9781906985417 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Royal College of Obstetricians and Gynaecologists Study Group Series |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3399991">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=3399991</a> |
| Public note | Click to View |
No items available.